Welcome to our dedicated page for Halberd news (Ticker: HALB), a resource for investors and traders seeking the latest updates and insights on Halberd stock.
Halberd Corporation (HALB) is an innovative biopharmaceutical company developing targeted therapies for PTSD, traumatic brain injury, and related mental health conditions through patented drug formulations and wearable monitoring technologies. This news hub provides investors and researchers with timely updates on the company's clinical trials, intellectual property developments, and strategic partnerships.
Access authoritative information about HALB's progress in mental health treatment innovation, including updates on its LDN+ and Tri-Ax nasal spray therapies. The repository consolidates press releases related to CRADA clinical trials, technology integrations with partners like Athena GTX, and patent filings that underpin the company's valuation.
Key content categories include regulatory milestones, research collaborations with military healthcare providers, and advancements in combined pharmaceutical/digital health solutions. All materials maintain compliance with OTC Market disclosure standards while emphasizing HALB's unique position at the intersection of biopharma and wearable diagnostics.
Bookmark this page for streamlined tracking of HALB's progress in addressing critical mental health challenges through evidence-based therapeutic innovation. Check regularly for verified updates that reflect the company's commitment to advancing both patient care and shareholder value.
Halberd Corporation (OTC PINK: HALB) has announced a collaborative research project with Arizona State University to develop a rapid diagnostic test for Covid-19. The focus is on the coronavirus spike antigen, which is critical to the virus's contagiousness. Feasibility samples of an antibody conjugate are expected in four weeks, potentially enabling a quick testing method using saliva or blood. The company holds exclusive rights to relevant provisional patents for Covid-19 treatments.
Halberd Corporation (OTC PINK: HALB) announced a significant breakthrough in its COVID-19 research project with Arizona State University. Dr. Qiang Chen's team successfully recreated the coronavirus spike protein disease antigen, paving the way for the identification of proprietary antibodies expected within two weeks. The joint efforts aim to secure patent protections for their findings. The company's patented extracorporeal process could improve detection and treatment of COVID-19 while minimizing side effects associated with traditional drug therapies.
Halberd Corporation (OTC PINK: HALB) has outlined the second stage goals of its $1.4 million partnership with Arizona State University. This stage focuses on utilizing a dialysis method to identify Covid-19 samples through the removal of fluorescent antibody-antigen complexes. Initial findings from the first phase are promising, with results expected soon. Halberd's technology aims to enhance diagnosis and treatment of Covid-19, with multiple methods under investigation for optimal effectiveness. The company remains debt-free and compliant with OTC reporting requirements.
Halberd Corporation (HALB) announced a $1.4 million research partnership with Arizona State University aimed at developing a rapid Covid-19 test. This will involve creating a fluorescent antibody to identify Covid-19 in various samples. The project includes two provisional patents: one for treating Covid-19 and another for rapid identification. Initial results are expected within a month. CEO William A. Hartman emphasized the urgency for rapid identification due to market needs. The company remains debt-free and fully compliant with reporting requirements.
Halberd Corporation announced the commencement of research at Arizona State University (ASU) aimed at developing antibodies related to COVID-19. This research supports two issued patents and three provisional patent applications focusing on the extracorporeal removal of the virus' antigens from blood. The CEO expressed confidence in ASU's capabilities, particularly in the initial research phase. Halberd holds exclusive rights to various COVID-19 treatment patents, enhancing its position in the healthcare space amid the pandemic.
Halberd Corporation (OTC PINK: HALB) has partnered with Arizona State University (ASU) for research focused on developing a Covid-19 treatment. ASU is a leading institution in health-related funding and innovation. CEO William A. Hartman emphasized ASU's strong research capabilities, which were evaluated against six other universities before the partnership. The project aims not only to tackle Covid-19 but also to address other blood-borne and neurologic diseases through their patented extracorporeal treatment process.
Halberd Corporation (OTC PINK: HALB) announced a partnership with Arizona State University (ASU) on August 31, 2020, to develop treatments for Covid-19. This project will support Halberd's existing patents and provisional applications for extracorporeal removal of the virus' antigens from blood. The focus is also on developing neutralizing antibodies and potential therapeutic medications. Halberd possesses exclusive rights to multiple Covid-19-related patents.
Halberd Corp. (OTC PINK: HALB) announced the successful completion of a partnership with a major research university to develop compounds for its patented extracorporeal treatment for Covid-19. The contract terms are finalized, and signatures are in process, with more details to be released soon. Halberd holds exclusive rights to multiple provisional patents related to Covid-19 treatments. The company is debt-free and compliant with OTC Market reporting requirements.
Halberd Corp. (OTC PINK: HALB) provides insights into its patented extracorporeal treatment for COVID-19 in a recent response from CEO William A. Hartman. The unique process aims to remove disease antigens from bodily fluids through a method akin to kidney dialysis, using complexing agents to attract and sequester these antigens. The company also holds provisional patents for multiple methods targeting COVID-19, emphasizing its distinct approach compared to conventional treatments. As a debt-free entity, Halberd is positioned to explore revolutionary medical techniques, although it faces potential regulatory scrutiny.
Halberd Corp. (OTC PINK: HALB) announced the appointment of Edson Brito to its Scientific Advisory Board. With extensive experience in sales and business development in the pharma sector, Brito aims to facilitate the advancement of COVID-19 treatments in international markets. Chairman William Hartman expressed confidence in Brito's expertise, particularly regarding the company's research and development efforts. Halberd holds exclusive rights to multiple provisional patents for COVID-19 treatment, emphasizing its commitment to addressing the pandemic.
FAQ
What is the current stock price of Halberd (HALB)?
What is the market cap of Halberd (HALB)?
